BCM
CSTL icon

BluePath Capital Management’s Castle Biosciences CSTL Stock Holding History

BluePath Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,811
Closed -$30.6K – 153
2023
Q3 		$30.6K Buy
+1,811
New +$31.7K 0.03% 282

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BluePath Capital Management's CSTL Position: Q4 2023 in Review

BluePath Capital Management sold out of Castle Biosciences (CSTL) in Q4 2023, closing a stake of 1,811 shares — an estimated $30.6K sold.

BluePath Capital Management first reported a position in CSTL in Q3 2023 and held it in 1 quarter. The position peaked at $30.6K in Q3 2023. 153 funds tracked by Wall St. Rank hold CSTL as of Q4 2023.

  • BluePath Capital Management reported no remaining Castle Biosciences position as of Q4 2023 after selling out during the quarter.
  • BluePath Capital Management sold 1,811 Castle Biosciences shares in Q4 2023, an estimated $30.6K.
  • BluePath Capital Management first reported a position in Castle Biosciences in Q3 2023 and held it in 1 quarter.
  • BluePath Capital Management's Castle Biosciences position peaked at $30.6K in Q3 2023.
  • 153 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2023.

Based on BluePath Capital Management's 13F filing for Q4 2023, filed 11 Jan 2024.